Marín-Hernández Alvaro, López-Ramírez Sayra Y, Del Mazo-Monsalvo Isis, Gallardo-Pérez Juan C, Rodríguez-Enríquez Sara, Moreno-Sánchez Rafael, Saavedra Emma
Departamento de Bioquímica, Instituto Nacional de Cardiología, Mexico.
FEBS J. 2014 Aug;281(15):3325-45. doi: 10.1111/febs.12864. Epub 2014 Jul 1.
The effect of hypoglycemia on the contents of glycolytic proteins, activities of enzymes/transporters and flux of HeLa and MCF-7 tumor cells was experimentally analyzed and modeled in silico. After 24 h hypoglycemia (2.5 mm initial glucose), significant increases in the protein levels of glucose transporters 1 and 3 (GLUT 1 and 3) (3.4 and 2.1-fold, respectively) and hexokinase I (HKI) (2.3-fold) were observed compared to the hyperglycemic standard cell culture condition (25 mm initial glucose). However, these changes did not bring about a significant increase in the total activities (Vmax ) of GLUT and HK; instead, the affinity of these proteins for glucose increased, which may explain the twofold increased glycolytic flux under hypoglycemia. Thus, an increase in more catalytically efficient isoforms for two of the main controlling steps was sufficient to induce increased flux. Further, a previous kinetic model of tumor glycolysis was updated by including the ratios of GLUT and HK isoforms, modified pyruvate kinase kinetics and an oxidative phosphorylation reaction. The updated model was robust in terms of simulating most of the metabolite levels and fluxes of the cells exposed to various glycemic conditions. Model simulations indicated that the main controlling steps were glycogen degradation > HK > hexosephosphate isomerase under hyper- and normoglycemia, and GLUT > HK > glycogen degradation under hypoglycemia. These predictions were experimentally evaluated: the glycolytic flux of hypoglycemic cells was more sensitive to cytochalasin B (a GLUT inhibitor) than that of hyperglycemic cells. The results indicated that cancer glycolysis should be inhibited at multiple controlling sites, regardless of external glucose levels, to effectively block the pathway.
The mathematical models described here have been submitted to the JWS Online Cellular Systems Modelling Database and can be accessed at http://jjj.mib.ac.uk/database/achcar/index.html. [Database section added 21 July 2014 after original online publication].
通过实验分析了低血糖对HeLa和MCF - 7肿瘤细胞糖酵解蛋白含量、酶/转运蛋白活性及通量的影响,并进行了计算机模拟。在低血糖处理24小时(初始葡萄糖浓度为2.5 mM)后,与高血糖标准细胞培养条件(初始葡萄糖浓度为25 mM)相比,观察到葡萄糖转运蛋白1和3(GLUT 1和3)(分别为3.4倍和2.1倍)以及己糖激酶I(HKI)(2.3倍)的蛋白水平显著增加。然而,这些变化并未导致GLUT和HK的总活性(Vmax)显著增加;相反,这些蛋白对葡萄糖的亲和力增加,这可能解释了低血糖条件下糖酵解通量增加两倍的原因。因此,两个主要控制步骤中更具催化效率的同工型增加足以诱导通量增加。此外,通过纳入GLUT和HK同工型的比例、修正的丙酮酸激酶动力学和氧化磷酸化反应,更新了先前的肿瘤糖酵解动力学模型。更新后的模型在模拟暴露于各种血糖条件下的细胞的大多数代谢物水平和通量方面表现稳健。模型模拟表明,在高血糖和正常血糖条件下,主要控制步骤为糖原降解 > HK > 磷酸己糖异构酶,而在低血糖条件下为GLUT > HK > 糖原降解。对这些预测进行了实验评估:低血糖细胞的糖酵解通量比高血糖细胞对细胞松弛素B(一种GLUT抑制剂)更敏感。结果表明,无论外部葡萄糖水平如何,应在多个控制位点抑制癌症糖酵解,以有效阻断该途径。
此处描述的数学模型已提交至JWS在线细胞系统建模数据库,可通过http://jjj.mib.ac.uk/database/achcar/index.html访问。[数据库部分于2014年7月21日在原始在线发表后添加]